
Kane Biotech
Actively advancing technologies and products that break up biofilms and destroy bacteria.
Date | Investors | Amount | Round |
---|---|---|---|
investor | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
* | N/A | CAD1.2m | Private Placement non VC |
Total Funding | 000k |
CAD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | 20 % | 234 % | (21 %) | 20 % | 66 % | (94 %) | 1297 % |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | (612 %) | (202 %) | (272 %) | (264 %) | (103 %) | (2087 %) | (178 %) |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | (644 %) | (57 %) | (277 %) | (286 %) | (146 %) | (3379 %) | 293 % |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
R&D % of revenue | 182 % | 91 % | 99 % | 86 % | 39 % | 707 % | 83 % |
Source: Company filings or news article
Related Content
Kane Biotech Inc. is a biotechnology company focused on the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms. The company operates in the biotechnology sector, serving clients across various industries that require biofilm management solutions, including healthcare, industrial, and consumer markets. Kane Biotech's business model revolves around developing proprietary technologies and products, which are then commercialized through partnerships, licensing agreements, and direct sales. Revenue is generated through product sales, licensing fees, and royalties from partnered products. The company leverages its extensive expertise in biofilm research to create innovative solutions that address significant challenges in biofilm management, thereby providing value to its clients and stakeholders.
Keywords: biotechnology, microbial biofilms, prevention, removal, healthcare, industrial, consumer markets, proprietary technologies, licensing, commercialization.
Tech stack
Investments by Kane Biotech
Edit